Video

Educated Patient® Breast Cancer Summit Multi-Disciplinary Approaches to Early-Stage Breast Cancer Session: November 13, 2021

Author(s):

CURE Media Group

View the full CURE Educated Patient Breast Cancer Summit Multi-Disciplinary Approaches to Early-Stage Breast Cancer Session on demand.

Related Videos
a man and a woman in front of a dark blue background
a man and a woman in front of a dark blue background
a man and a woman in separate boxes in front of a dark blue background
Image of doctor with brown hair.
Image of Doctor with blonde hair.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of bald man.
Related Content
Image of woman holding her chest.
March 7th 2025

BRCA1/2 Mutations May Associate With Better Chemo Response in TNBC

Alex Biese
Among patients with early-stage triple-negative breast cancer, a beneficial pathologic complete response rate was higher in patients with BRCA1/2 mutations.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Image of woman holding pink ribbon.
March 4th 2025

Verzenio Combo May Improve Survival in HR+/HER2– Advanced Breast Cancer

Spencer Feldman
Verzenio plus Faslodex improved progression-free survival in HR+/HER2– advanced breast cancer after CDK/6i failure, with a manageable safety profile.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Camizestrant combo had a statistically significant and clinically meaningful improvement in PFS in advanced breast cancer; © Pixel-Shot - stock.adobe.com
March 1st 2025

Camizestrant Combo Improves Progression Time in HR+/HER2– Breast Cancer

Ryan Scott
Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in HR+/HER2– advanced breast cancer.
Illustration of woman with black hair.
February 27th 2025

My Cousin and I Journey Through Breast, Lung, Pancreatic and Prostate Cancer

Sue McCarthy
After realizing that a stronger support system would have helped me emotionally and spiritually in my cancer journey, I committed myself to being there for my cousin.